NCCS applauds the nomination of Dr. Scott Gottlieb for commissioner of the FDA. Dr. Gottlieb’s experience as a physician, a policymaker, and a patient uniquely qualifies him to lead the FDA at this important time. The agency confronts a rich pipeline of new products for cancer and other illnesses, and these products raise complicated scientific and clinical issues. FDA must also implement the provisions of the 21st Century Cures [...]

What Caught Our Eye is our week-in-review blog series, where we recap the cancer policy articles, studies, and stories that caught our attention. The American Health Care Act (AHCA) was introduced in the House earlier this week. A great deal has been written analyzing this legislation. STAT News has an honest and sobering article about the need to “do better in communicating the reality of cancer care to patients.” [...]

The AHCA seeks to repeal and replace significant portions of the current health care law, the Affordable Care Act (ACA). Even upon initial review, there is no question that the American Health Care Act (AHCA) is a significant step backward from the ACA’s affordability and patient protections, and will hurt millions of Americans, including cancer patients and survivors. [...]